Report : Middle East & Africa Glycomics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Enzymes, Instruments, Kits, and Reagents), Application (Drug Discovery and Development, Diagnostics, Immunology, Cancer, and Others), and End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations)
At 12.0% CAGR, the MEA Glycomics Market is speculated to be worth US$ 140.21 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the MEA glycomics market was valued at US$ 71.00 million in 2022 and is expected to reach US$ 140.21 million by 2028, registering an annual growth rate of 12.0% from 2022 to 2028. New tools in glycomics research and wide applications of glycomics are the critical factors attributed to the market expansion.
By enhancing the characterization of molecules crucial to the development of diseases, glycomics has the potential to pave the way for innovative treatment approaches. It can be a substantial addition to technologies used in genomes and proteomics. Comparative glycomics will be essential for identifying the glycans that cause disease, and more studies will provide light on the relationship between clinical outcomes and glycomic anomalies. Immunohistochemistry (IHC), Liquid Chromatography-Mass Spectrometry (LC-MS), and high-throughput fluorescence flow cytometry have long been used to distinguish cell populations using glycoproteins. These are the important technologies utilized to advance glycomics. By separating several glycoprotein isoforms from a single protein species, LC-MS can provide structural details about glycoconjugates. Unbiased surveys of cellular proteomes are now available due to high-throughput MS-based proteomics, and the method is swiftly applied to glycomics. Structural reference databases are quickly emerging to close the gap between the variety and complexity of glycan structures. Identification of disease-related glycoconjugates by LC-MC, which employs antibody-based capture to view glycoconjugate expression with cell-staining or fluorescence, can be used to further assess or validate IHC. Targeting complete cells rather than tissue fragments, immunocytochemistry (ICC) reveals glycoprotein expression patterns at the cellular level utilizing the same imaging techniques as IHC. It will be possible to see new aspects of glycomics, such as a more thorough characterization of metabolic junctions and pathways, by modifying IHC and ICC to concentrate on additional glycoconjugates, such as glycolipids. Tandem or multi-technology procedures, such as MS-IHC, will provide labs with more analytical ability to handle the complexity of glycoconjugates and improve glycoconjugate diagnosis. The clinical applications of glycomics are catching up to those of genomics and proteomics due to the development of new high-throughput methods to study the structure and expression of glycans and ongoing innovation in glycan biomarkers and therapies. Integrating glycomics will revolutionize precision medicine into an extensive omics strategy, providing new information on the interactions between genes, proteins, and glycans. The combination of omics data with digital health platforms has the potential to improve clinical trials and aid in the creation of more complex knowledge of illness among researchers and doctors. Although these and other scientific discoveries are making their way from the lab to the clinic, widespread acceptance of glycomics and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized health care challenges will be met and overcome with the assurance that the research behind glycomic medicine is decent and that the practice of medicine that it informs is evidence-based. So, new tools in glycomics research is expected to drive the market in coming years.
On the contrary, high cost of equipment and shortage of skilled professionals hurdles the growth of MEA glycomics market.
Based on product, the MEA glycomics market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment held 43.6% market share in 2022, amassing US$ 30.98 million. It is projected to garner US$ 62.63 million by 2028 to expand at 12.5% CAGR during 2022–2028. The enzymes segment is further segmented into glycosidases, glycosyl transferases, sialyltransferases, neuraminidases, and others. The instruments segment is also segmented into mass spectrometers, MALDI-TOF, HPLC, lectin arrays, antibody arrays, and others. Similarly, the kits segment is segmented into glycan release kits, glycan labeling kits, glycan purification kits, and others. Furthermore, the reagents segment is segmented into oligosaccharides, monosaccharides, glycoproteins, and others.
Based on application, the MEA glycomics market is segmented into drug discovery and development, diagnostics, immunology, cancer, and others. The drug discovery and development segment held 33.4% market share in 2022, amassing US$ 23.75 million. It is projected to garner US$ 47.90 million by 2028 to expand at 12.4% CAGR during 2022–2028.
Based on end user, the MEA glycomics market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations. The pharmaceutical & biotechnology companies segment held 48.9% market share in 2022, amassing US$ 34.69 million. It is projected to garner US$ 70.26 million by 2028 to expand at 12.5% CAGR during 2022–2028.
Based on country, the MEA glycomics market has been categorized into the UAE, Saudi Arabia, South Africa, and rest of MEA. Our regional analysis states that Saudi Arabia captured 39.5% market share in 2022. It was assessed at US$ 28.04 million in 2022 and is likely to hit US$ 56.94 million by 2028, exhibiting a CAGR of 12.5% during the forecast period.
Key players dominating the MEA glycomics market are Agilent Technologies, Inc.; Bruker Corporation; MERCK KGaA; New England Biolabs; Shimadzu Corporation; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and Waters Corporation among others.
- In June 2021, Waters Corporation introduced the Waters SELECT SERIES, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources. Together, these technologies enabled scientists to explore molecular structure and function through the precise identification and localization of individual molecules in samples, with a unique combination of speed, resolution, and mass accuracy.
- In June 2022, Thermo Fisher Scientific Inc. and TransMIT GmbH Center for Mass Spectrometric Developments have entered into a co-marketing agreement to promote the use of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharma and clinical labs. As part of the relationship, TransMIT combines its proprietary scanning microprobe matrix-assisted laser desorption/ionization (SMALDI) MSI and 3D-surface MSI technology with the Thermo Scientific Orbitrap MS instrumentation. It can be applied to omics applications such as proteomics, glycomics and to pharmaco-kinetic studies in a variety of tissues.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org